Rapid accurate point-of-care tests combining diagnostics and antimicrobial resistance prediction for Neisseria gonorrhoeae and Mycoplasma genitalium
- PMID: 28684610
- DOI: 10.1136/sextrans-2016-053072
Rapid accurate point-of-care tests combining diagnostics and antimicrobial resistance prediction for Neisseria gonorrhoeae and Mycoplasma genitalium
Abstract
In addition to inadequate access to early diagnosis and treatment with antimicrobial agents for patients and sexual contacts, management and control of STIs is significantly challenged by emergence and spread of antimicrobial resistance (AMR), particularly for STIs such as Neisseria gonorrhoeae and Mycoplasma genitalium This is further compounded by use of nucleic acid amplification techniques for diagnosis, resulting in reduced phenotypic AMR testing for N. gonorrhoeae and absence or suboptimal AMR surveillance for guiding treatment of both STIs in many settings. Rapid accurate point-of-care (POC) tests for diagnosis of all STIs would be valuable but to significantly impact treatment precision and management of N. gonorrhoeae and M. genitalium infections, combinations of rapid POC diagnostic and AMR testing (POC-AMR) will likely be required. This strategy would combat STI burden and AMR emergence and spread by enabling diagnosis and individualised treatment at the first healthcare visit, potentially reducing selection pressure on recommended antimicrobials, reducing transmission of resistant strains and providing means for AMR surveillance. Microfluidic and nanotechnology platforms under development for rapid detection of STIs provide a basis to also develop molecular rapid POC-AMR prediction. A number of prototypic devices are in the pipeline but none as yet approved for routine use. However, particularly for N. gonorrhoeae, more knowledge is required to assess which antimicrobials lend themselves to a genotypic POC-AMR approach, in relation to genotypic-phenotypic associations and potential impact clinically and epidemiologically. Key for successful deployment will include also understanding cost-effectiveness, cost-consequences and acceptability for key stakeholders.
Keywords: ANTIMICROBIAL RESISTANCE; DIAGNOSIS; DNA AMPLIFICATION; M GENITALIUM; NEISSERIA GONORRHOEA.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Conflict of interest statement
Competing interests: STS is grant holder for the National Institute for Health Research (NIHR) i4i Programme (grant number II-LB-0214-20005). The views expressed are those of the authors and not necessarily those of the NIHR, the NHS or the UK Department of Health. STS has also received funding from Atlas Genetics to conduct performance evaluations of its io POC system. None for MU and FM.
Similar articles
-
Antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium isolates from the private healthcare sector in South Africa: A pilot study.S Afr Med J. 2021 Oct 5;111(10):995-997. doi: 10.7196/SAMJ.2021.v111i10.15714. S Afr Med J. 2021. PMID: 34949296
-
In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.Antimicrob Agents Chemother. 2014 Jun;58(6):3151-6. doi: 10.1128/AAC.02411-14. Epub 2014 Mar 17. Antimicrob Agents Chemother. 2014. PMID: 24637681 Free PMC article.
-
Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium.Nat Rev Urol. 2017 Mar;14(3):139-152. doi: 10.1038/nrurol.2016.268. Epub 2017 Jan 10. Nat Rev Urol. 2017. PMID: 28072403 Review.
-
Rapid Detection of Antimicrobial Resistance in Mycoplasma genitalium by High-Resolution Melting Analysis with Unlabeled Probes.Microbiol Spectr. 2022 Aug 31;10(4):e0101422. doi: 10.1128/spectrum.01014-22. Epub 2022 Jul 26. Microbiol Spectr. 2022. PMID: 35880894 Free PMC article.
-
A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa.J Antimicrob Chemother. 2022 Jul 28;77(8):2074-2093. doi: 10.1093/jac/dkac159. J Antimicrob Chemother. 2022. PMID: 35578892 Free PMC article.
Cited by
-
PARMAP: A Pan-Genome-Based Computational Framework for Predicting Antimicrobial Resistance.Front Microbiol. 2020 Oct 22;11:578795. doi: 10.3389/fmicb.2020.578795. eCollection 2020. Front Microbiol. 2020. PMID: 33193203 Free PMC article.
-
Point-of-Care Testing for Sexually Transmitted Infections: A Review of Recent Developments.Arch Pathol Lab Med. 2020 Nov 1;144(11):1344-1351. doi: 10.5858/arpa.2020-0118-RA. Arch Pathol Lab Med. 2020. PMID: 32810868 Free PMC article. Review.
-
Is It Time for the United States and Canada to Reconsider Macrolides as the First-line Empiric Treatment for Males With Symptomatic Urethritis?Clin Infect Dis. 2020 Feb 14;70(5):811-813. doi: 10.1093/cid/ciz297. Clin Infect Dis. 2020. PMID: 30972414 Free PMC article. No abstract available.
-
Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward.J Int AIDS Soc. 2019 Aug;22 Suppl 6(Suppl Suppl 6):e25343. doi: 10.1002/jia2.25343. J Int AIDS Soc. 2019. PMID: 31468679 Free PMC article.
-
The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.Transl Res. 2020 Jun;220:122-137. doi: 10.1016/j.trsl.2020.02.002. Epub 2020 Feb 29. Transl Res. 2020. PMID: 32119845 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical